Here2Learn
Member
Just thought I would share my experience running ara-290. I originally thought it would make a great option so I could cycle off Kpv and still have some inflammation control. KPV has been stellar in reducing pain and inflammation but I figure it would be good to run in cycles.
Ara-290 wouldn’t qualify as a replacement imo, it does take weeks to really take effect though. All the sudden I noticed an area in my leg that has some nerve damage not having the odd sensations anymore. I had slight swelling there, blood flow felt lacking and it was either hotter or colder than the skin around it. Now it feels closer to the rest of my leg. I did have sparkling feeling in my fingers and odd places off and on the first couple of weeks it started. This peptide is known to be good for nerve pain and I will say it is worth a try for anyone having an issue.
ARA-290, also known as cibinetide, has received orphan drug designations from the FDA for two indications: sarcoidosis and the treatment of neuropathic pain in patients with sarcoidosis. Additionally, it has received orphan drug designation from the EMA for the prevention of graft loss in pancreatic islet cell transplants
Ara-290 wouldn’t qualify as a replacement imo, it does take weeks to really take effect though. All the sudden I noticed an area in my leg that has some nerve damage not having the odd sensations anymore. I had slight swelling there, blood flow felt lacking and it was either hotter or colder than the skin around it. Now it feels closer to the rest of my leg. I did have sparkling feeling in my fingers and odd places off and on the first couple of weeks it started. This peptide is known to be good for nerve pain and I will say it is worth a try for anyone having an issue.
ARA-290, also known as cibinetide, has received orphan drug designations from the FDA for two indications: sarcoidosis and the treatment of neuropathic pain in patients with sarcoidosis. Additionally, it has received orphan drug designation from the EMA for the prevention of graft loss in pancreatic islet cell transplants